378 filings
8-K
EGRX
Eagle Pharmaceuticals Inc
12 Apr 24
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Forward-Looking Statements Disclaimer
4:16pm
NT 10-K
EGRX
Eagle Pharmaceuticals Inc
18 Mar 24
Notice of late annual filing
8:00am
8-K
EGRX
Eagle Pharmaceuticals Inc
8 Mar 24
Departure of Directors or Certain Officers
4:49pm
8-K
EGRX
Eagle Pharmaceuticals Inc
1 Mar 24
Entry into a Material Definitive Agreement
7:35am
8-K
EGRX
Eagle Pharmaceuticals Inc
29 Feb 24
Cost Associated with Exit or Disposal Activities
8:09am
8-K
t75opf3c1i k2bwg2t
13 Feb 24
Other Events
8:50am
8-K
k972du
18 Jan 24
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
6:56am
8-K
5cmg9729cdb0
16 Jan 24
Entry into a Material Definitive Agreement
7:00am
8-K/A
4pif zk4gc
22 Dec 23
Departure of Directors or Certain Officers
5:15pm
8-K
dj6yrd si7l0
15 Dec 23
Results of Operations and Financial Condition
5:11pm
8-K
ijge3i5t3 2b89jz1m
6 Dec 23
Regulation FD Disclosure
4:26pm
8-K
hx2s5qv2
29 Nov 23
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
7:39am
8-K
rcq7p8c 9skuc
29 Nov 23
Eagle Pharmaceuticals Announces Management Change
7:36am
NT 10-Q
lwgpnr ev79qpgmv8o0
9 Nov 23
Notice of late quarterly filing
5:23pm
8-K
mxzm 0uwbuh2hia8hsvw
9 Nov 23
Eagle Delays Third Quarter 2023 Results and Conference Call
7:57am
8-K
n7jrayw
24 Oct 23
Regulation FD Disclosure
8:49am
8-K
kxkixrdyitxqal5dr
23 Oct 23
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
7:10am
8-K
wj63gdsb649am7xsl4
27 Sep 23
Regulation FD Disclosure
7:00am
8-K
dmoesrc9gka tiz1wfov
7 Sep 23
Regulation FD Disclosure
7:20am
8-K
iuhxiw8b em
29 Aug 23
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of
6:55am